Unlocking Q2 Potential of Insulet (PODD): Exploring Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Insulet (PODD) Earnings Expected to Grow: Should You Buy?
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insulet expects to beat revenue estimates on strong insulin pump demand
Insulet reported preliminary second-quarter revenue above Wall Street estimates on Friday, as it benefited from strong demand for its insulin delivery devices.
All You Need to Know About Insulet (PODD) Rating Upgrade to Strong Buy
Insulet (PODD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes
Insulet (PODD) reports positive findings from the SECURE-T2D pivotal trial, the largest study of AID therapy in people with type 2 diabetes.
Insulet (PODD) Unveils Key Achievements for the Omnipod 5 System
Insulet (PODD) debuts the Omnipod 5 AID system in France and announces new updates for the U.S. markets.
Is Insulet (PODD) Stock an Apt Pick for Your Portfolio Now?
The robust performance of Insulet's (PODD) Omnipod 5 raises investors' optimism. However, concerns remain over the macroeconomic impacts and the company's overdependence on a single platform.
Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023
Insulet Corporation saw a significant drop in stock price in 2023 due to concerns over the impact of GLP-1 weight loss drugs on the insulin pump industry. These fears seem to be largely overblown, however, meaning that Insulet is arguably still trading at a substantial discount to its true value as a company. Insulet's CEO believes that GLP-1 drugs are increasing the adoption of insulin, not decreasing it, suggesting a positive impact on the iCGM industry.
Here's Why Insulet (PODD) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
